Related Experiment Video
Updated: Oct 15, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Low-dose colchicine: a potential augmenting agent in the treatment of refractory mood disorders
Ajeet B Singh1, David R Skvarc2, Juliana Lago3
1Deakin University, School of Medicine, Institute for Mental and Physical Health and Clinical Translation, Australia.
Abstract:
Treatment-resistant mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), remain a significant clinical challenge. A confluence of emerging evidence implicates chronic low-grade inflammation in the pathophysiology of at least a subset of mood disorders, potentially mediating their poor response to traditional therapies. Colchicine, a well-established anti-inflammatory agent used in gout and more recently (at low dose) cardiovascular disease, inhibits microtubule polymerisation and suppresses NLRP3 inflammasome activation. Recent advances in immunopsychiatry suggest NLRP3-mediated pathways are key mediators of mood pathology. This hypothesis-generating paper explores how low-dose colchicine may plausibly serve as a novel augmenting agent in refractory mood disorders by targeting these neuroinflammatory pathways. We present mechanistic rationale, integrate preclinical and translational evidence, review long-term safety data and outline biomarker-guided clinical trial proposals.
Related Concept Videos
Drugs that Destabilize Microtubules
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Antidepressant Drugs: MAOIs and Other Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids